KPIT Cummins is a leading Indian IT company focused on automotive engineering and manufacturing. It has grown revenues at a CAGR of over 40% in recent years through its focus on key verticals and strategic acquisitions that have expanded its service offerings. In the first half of FY2013, KPIT reported strong revenue and profit growth with margins improving. The company is well positioned for continued outperformance relative to its mid-cap IT peers due to its domain expertise and differentiated vertical focus strategy.
KPR Mill reported 15.4% revenue growth in 9mFY12 but profitability was impacted by Tamil Nadu's power shortage. While KPR's exports grew strongly, output was reduced in Q3FY12 due to lower utilization from power cuts. Cotton prices stabilized after an initial sharp fall resulted in a one-time inventory write-down for KPR. The company's FY13 outlook is positive as the full benefits of its expanded yarn capacity will be realized and power availability is expected to improve in the second half of the year. However, near-term estimates have been reduced due to the expected impact of continuing power issues in the first quarter of FY13.
Venus Remedies has shown positive progress from its research and development pipeline with two innovative products receiving US patent approvals. This marks an important milestone in validating Venus' R&D investments. In Q1 FY2013, Venus reported revenue growth of 13.3% and maintained healthy margins. It also launched a new cancer product called Taxedol and received two additional significant US patents for antibiotic products, demonstrating further results from its research efforts. The company is believed to have upside potential from its ongoing research gains.
Vinati Organics is a specialty chemical company that has achieved global leadership in its two key products, IBB and ATBS. While IBB contributed significantly to sales in the past, its contribution is declining as the company diversifies its product mix. Vinati has delivered strong revenue growth over 40% CAGR and improving margins in recent years. Going forward, the company is expected to continue its revenue growth above 30% driven by capacity expansion and new product introductions. Vinati differentiates itself through its focus on niche chemical products with proprietary technology not easily available to competitors.
HESCOM has launched a net metering program to promote rooftop solar projects. Under the program, consumers can install solar panels on their roofs up to a capacity of 500kWp. When solar generation exceeds usage, excess energy will be exported to the grid and the consumer will be paid for it. When energy usage exceeds solar generation, energy will be imported from the grid. Consumers must submit an application, technical details, and execute a PPA to participate. The program aims to encourage distributed solar generation and allow consumers to benefit from selling excess solar energy to the grid.
KPR Mill is one of the top five yarn producers and largest garment manufacturers in India. It has vertically integrated operations across the textile value chain. The company is increasing its yarn capacity by 60% in FY12 and will achieve 100% power self-sufficiency in FY13 by commissioning a co-generation cum sugar project. This will lead to higher capacity utilization and reduced costs. KPR has demonstrated strong revenue growth, superior margins, and high dividend payouts compared to peers. It is well positioned for further expansion with its innovative management practices and state-of-the-art facilities.
Rooftop solar projects with net meterings is possible in Bangalore. This presentation provides details about the process to get the projects implemented. The source of the information is from BESCOM and KERC as per latest orders.
Venus Remedies is an Indian pharmaceutical company focused on the injectables segment. It has two key strengths - presence in high-growth therapeutic areas like anti-infectives and oncology, and a strong research focus resulting in novel drug formulations. Some key products from its research pipeline include Sulbactomax, an anti-infective to treat drug-resistant bacteria, which has the potential for global licensing deals. Venus maintains high operating margins through focus on specialized, high-margin injectable products and segments. It has a large patent portfolio from its R&D efforts and aims to monetize this intellectual property wealth through further licensing agreements.
KPIT Cummins is a leading Indian IT company focused on automotive engineering and manufacturing. It has grown revenues at a CAGR of over 40% in recent years through its focus on key verticals and strategic acquisitions that have expanded its service offerings. In the first half of FY2013, KPIT reported strong revenue and profit growth with margins improving. The company is well positioned for continued outperformance relative to its mid-cap IT peers due to its domain expertise and differentiated vertical focus strategy.
KPR Mill reported 15.4% revenue growth in 9mFY12 but profitability was impacted by Tamil Nadu's power shortage. While KPR's exports grew strongly, output was reduced in Q3FY12 due to lower utilization from power cuts. Cotton prices stabilized after an initial sharp fall resulted in a one-time inventory write-down for KPR. The company's FY13 outlook is positive as the full benefits of its expanded yarn capacity will be realized and power availability is expected to improve in the second half of the year. However, near-term estimates have been reduced due to the expected impact of continuing power issues in the first quarter of FY13.
Venus Remedies has shown positive progress from its research and development pipeline with two innovative products receiving US patent approvals. This marks an important milestone in validating Venus' R&D investments. In Q1 FY2013, Venus reported revenue growth of 13.3% and maintained healthy margins. It also launched a new cancer product called Taxedol and received two additional significant US patents for antibiotic products, demonstrating further results from its research efforts. The company is believed to have upside potential from its ongoing research gains.
Vinati Organics is a specialty chemical company that has achieved global leadership in its two key products, IBB and ATBS. While IBB contributed significantly to sales in the past, its contribution is declining as the company diversifies its product mix. Vinati has delivered strong revenue growth over 40% CAGR and improving margins in recent years. Going forward, the company is expected to continue its revenue growth above 30% driven by capacity expansion and new product introductions. Vinati differentiates itself through its focus on niche chemical products with proprietary technology not easily available to competitors.
HESCOM has launched a net metering program to promote rooftop solar projects. Under the program, consumers can install solar panels on their roofs up to a capacity of 500kWp. When solar generation exceeds usage, excess energy will be exported to the grid and the consumer will be paid for it. When energy usage exceeds solar generation, energy will be imported from the grid. Consumers must submit an application, technical details, and execute a PPA to participate. The program aims to encourage distributed solar generation and allow consumers to benefit from selling excess solar energy to the grid.
KPR Mill is one of the top five yarn producers and largest garment manufacturers in India. It has vertically integrated operations across the textile value chain. The company is increasing its yarn capacity by 60% in FY12 and will achieve 100% power self-sufficiency in FY13 by commissioning a co-generation cum sugar project. This will lead to higher capacity utilization and reduced costs. KPR has demonstrated strong revenue growth, superior margins, and high dividend payouts compared to peers. It is well positioned for further expansion with its innovative management practices and state-of-the-art facilities.
Rooftop solar projects with net meterings is possible in Bangalore. This presentation provides details about the process to get the projects implemented. The source of the information is from BESCOM and KERC as per latest orders.
Venus Remedies is an Indian pharmaceutical company focused on the injectables segment. It has two key strengths - presence in high-growth therapeutic areas like anti-infectives and oncology, and a strong research focus resulting in novel drug formulations. Some key products from its research pipeline include Sulbactomax, an anti-infective to treat drug-resistant bacteria, which has the potential for global licensing deals. Venus maintains high operating margins through focus on specialized, high-margin injectable products and segments. It has a large patent portfolio from its R&D efforts and aims to monetize this intellectual property wealth through further licensing agreements.
Company report reliance broadcast network 17th april 2012Four-S
RBN is rapidly building a strong presence in the Indian media and entertainment industry. Within 6 years, RBN's BIG FM radio network has become the largest private radio network by scale and the second largest by revenues. RBN also has a 5 channel broadcasting portfolio and is entering the profitable phases of its radio and television businesses. RBN's international joint ventures and content production capabilities position it for continued high growth across radio, television, and other segments in the coming years.
Atlanta ended the fiscal year 2012 with an order book exceeding Rs. 24 billion, over 4 times expected revenues for fiscal year 2013. This positions the company for strong growth going forward. Three new road projects worth Rs. 27 billion were won in fiscal year 2012 and are key drivers of anticipated growth. Two operational build-operate-transfer road projects are also expected to contribute improved cash flows in fiscal years 2013 and 2014. The company remains attractively valued given its portfolio of road projects and other infrastructure and real estate developments.
Zensar Technologies is an IT company that ended the 2011 fiscal year strongly positioned for growth. The acquisition of Akibia in November 2010 makes Zensar a leader in infrastructure management among midcap IT companies. Zensar has also reorganized around focus verticals, which will allow it to better cross-sell services and mine existing clients. The company now has a robust business model and stronger financials than many peers, including better margins, capital efficiency, and free cash flow generation.
Four s weekly pe track 30th july - 5th august 2012Four-S
During the week of July 30th to August 5th, there were 12 private equity deals worth $1.1 billion compared to 7 deals worth $34.2 million the previous week. The largest deal was Bain Capital Partners agreeing to buy 30% of Genpact for $1 billion. Other deals included L Capital investing $19.6 million in PVR, Oman India Joint Fund investing $13 million in Solar Industries India, and Vistaar Financial Services raising $7.2 million from Lok Capital and others. Private equity activity in India continued with deals across sectors such as IT/ITeS, manufacturing, retail, and financial services.
Four s fortnightly logistics track 7th august - 20th august 2012Four-S
- Future Supply Chain Solutions plans to raise $1 billion in a second round of private equity funding to double its warehousing capacity. It had previously raised $30 million in 2009.
- Gateway Distriparks reported revenues of $110 million for 2012-13, down from $120 million the previous year, while net profits fell to $33 million from $40 million.
- Gateway Distriparks aims to increase container freight station capacity to 560,000 TEUs this year and resume full operations at facilities in Punjab and Kochi.
Four s fortnightly education track 6th august - 20th august 20123Four-S
The document summarizes the following:
1) The Central Board of Secondary Education (CBSE) and the Pearson Foundation will set up a centre for assessment, evaluation and research, marking the first concrete move by the Indian government towards fostering public-private partnership (PPP) in education.
2) The centre will focus on developing research and assessment capabilities and resources for CBSE, its network of schools and teachers, focusing on international best practices in school-based assessment, teaching techniques and high-stake examinations.
3) While CBSE will provide infrastructure, Pearson will take care of operational expenditure, including teacher salaries, in the initial two-year phase as the government seeks to improve education access and quality
Four s weekly pe track 30th july - 5th august 2012Four-S
Bain Capital bought a 30% stake in Genpact for $1bn, the largest PE deal of the week. L Capital invested $19.6mn in PVR and its subsidiary to focus on in-mall entertainment. Oman India Joint Investment Fund invested $13mn in Solar Industries India, an industrial explosives maker, for a 4.28% stake.
Four s fortnightly logistics track 7th august - 20th august 2012Four-S
The document discusses several logistics industry news items:
1) Dempo Group acquired a controlling stake in shipyard Modest Infrastructure for $140 million to expand into shipbuilding and repair.
2) Future Supply Chain Solutions plans to raise $1 billion to double its warehousing capacity.
3) Gateway Distriparks expects higher profits this year from new container freight stations becoming operational.
4) Private equity firm GTI Capital invested in foods logistics company Brattle Foods to expand its facilities.
Four s weekly pe track 9th july - 15th july 2012Four-S
The document summarizes recent private equity deals in India during the week of July 8th to July 15th, 2012. It discusses 5 PE/VC deals worth a total of $66.5 million, including Carlyle buying a 9.96% stake in Infotech Enterprises for $38 million. It also mentions Big Shoe Bazaar raising $18 million in Series C funding led by Fidelity Growth Partners and Qualcomm Ventures, and Mobikon Asia raising $1.7 million from Jungle Ventures and others. SAIF Partners is also described as buying an additional 2.78% stake in Blue Star for $8.8 million.
The document provides an overview of the logistics and supply chain sector in India. It notes that the sector size was around US$XXX billion in 2010-11, and is expected to grow to US$XXX billion by 2014-15 and US$XXX billion by 2019-20. Road transport is the largest segment currently, generating around US$56 billion in 2010-11. The executive summary highlights several attractive segments within the industry such as EXIM logistics, agri logistics, and third-party logistics. The report also profiles major listed and unlisted companies operating in the Indian logistics space.
Four s weekly pe track 28th may-3rd june2012Four-S
1) During the week ended June 3rd, 2012 there were 8 PE/VC deals worth $32.1 million compared to 9 deals worth $39 million the previous week.
2) The largest deal was Carlyle Ventures investing Rs 600 million ($10.7 million) for a 2% stake in South Indian Bank Limited.
3) Tiger Global and SAIF Partners invested $10 million in online retailer Zovi.com for growth stage funding.
Four s fortnightly mediatainment track 18th may - 31st may 2012Four-S
- India's GDP declined to a 9 year low, which will negatively impact media industry ad revenues in FY2013 as they are dependent on GDP. Zee forecasts 8-10% industry growth for FY2013 but aims to grow faster through market share gains and subscription revenue increases.
- Regional media and retail advertising performed better than national players. Print players expanded geographically but faced higher newsprint costs. Radio players expect over 10% revenue growth.
- The Indian M&E sector is reinventing itself with multiple revenue streams, geographic and digital expansion, supported by government regulatory moves around digitization and spectrum auctions.
Four s weekly pe track 28th may-3rd june2012Four-S
1) During the week ended June 3rd, 2012 there were 8 PE/VC deals worth $32.1 million compared to 9 deals worth $39 million the previous week.
2) The largest deal was Carlyle Ventures investing Rs 600 million ($10.7 million) for a 2% stake in South Indian Bank Limited.
3) Tiger Global and SAIF Partners invested $10 million in online retailer Zovi.com for growth stage funding.
India's largest solar program in Gujarat has cut rates paid to utilities for solar power by up to 33% as global panel prices have declined by more than half. The new rates for projects commissioned after January 28th will be Rs 9.98/kWh for the first 12 years and Rs 7/kWh for the next 13 years, down from Rs 15/kWh. India is lowering clean energy subsidies as equipment costs plunge. The document also provides an overview of cleantech private equity deals in the last 6 months of 2011 and first quarter of 2012, totaling $28.3 million, and information on carbon credit prices and clean energy news updates.
Four s weekly pe track 2nd april - 8th april 2012Four-S
During the week ended April 8th, 2012, there were 7 private equity deals worth $217 million compared to 12 deals worth $39.7 million the previous week. The largest deal was Advent International's $105 million investment in CARE Hospitals. Additionally, GIC and Baring PE invested $100 million in Marico Ltd and India Agri Business Fund invested $9.8 million in Super Agri Seeds. There were also smaller deals involving HMS Infotech, Savaari Car Rentals, and Godrej Landmark Redevelopers. Healthcare continues to be an active sector for private equity deals in India.
The document provides an overview of the solar energy sector in India. It notes that India has significant untapped solar potential but has realized less than 20% of its renewable energy capacity. Solar PV is the main technology used in India, concentrated in small-scale applications and lighting. Key challenges include the high cost of solar power generation due to high capital costs. The National Solar Mission aims to increase solar capacity through generation incentives and policies supporting manufacturers. Several companies are profiled that manufacture solar components and develop utility-scale solar plants in India.
Four s weekly pe track 19th march - 25th march 2012Four-S
During the week, there were 7 PE/VC deals worth $35 million compared to 10 deals worth $302.5 million the previous week. The largest deal saw Parsvnath Developers raise $23.6 million from Kotak Realty Fund for a township project in Gurgaon. There were also PE investments in DTL Ancillaries, Prajay Engineers, Akshara Foundation, and Edutor Technologies. In M&A, Amcor acquired Uniglobe Packaging for $20.7 million in the largest deal of the week.
Four s fortnightly education track 15th march - 31st march 2012Four-S
The Indian government has invited private companies to partner in opening 2,500 secondary schools over the next five years. Companies can qualify for schools based on their net worth, experience running schools, and deposit amounts. The government will provide infrastructure grants and pay for education costs of underprivileged students. Other news included the AICTE banning new engineering and management colleges, plans for a common medical entrance exam in 2013, and 76% of Right to Education violations remaining unresolved. Private investments in the education sector included deals by Omidyar Network, Mumbai Angels, and Hyderabad Angels. Stocks of major education companies like Core Education and Educomp showed mixed performance over the last year.
Four s fortnightly pharma health track 23th january - 5th febuary 2012Four-S
The document is a newsletter on the Indian healthcare industry from Four-S Services covering the period of January 23rd to February 5th, 2011. It discusses positive quarterly results for major healthcare companies in India with 28% year-over-year revenue growth. It also summarizes Dr. Reddy's Laboratories quarterly results with an 87.8% increase in net profit. The newsletter provides updates on private equity investment activity, mergers and acquisitions, regulatory news, and upcoming events in the healthcare sector.
Four s weekly pe track 16 january - 22nd january 2012Four-S
During the week of January 16-22, 2012 there were 10 private equity deals worth $281.2 million. The largest deal was Temasek Holdings acquiring a 4.9% stake in Godrej Consumer Products for $135 million. There were also investments in healthcare, real estate, technology, and other sectors. Private equity firms were actively fundraising, investing, and seeking exits during this period.
Company report reliance broadcast network 17th april 2012Four-S
RBN is rapidly building a strong presence in the Indian media and entertainment industry. Within 6 years, RBN's BIG FM radio network has become the largest private radio network by scale and the second largest by revenues. RBN also has a 5 channel broadcasting portfolio and is entering the profitable phases of its radio and television businesses. RBN's international joint ventures and content production capabilities position it for continued high growth across radio, television, and other segments in the coming years.
Atlanta ended the fiscal year 2012 with an order book exceeding Rs. 24 billion, over 4 times expected revenues for fiscal year 2013. This positions the company for strong growth going forward. Three new road projects worth Rs. 27 billion were won in fiscal year 2012 and are key drivers of anticipated growth. Two operational build-operate-transfer road projects are also expected to contribute improved cash flows in fiscal years 2013 and 2014. The company remains attractively valued given its portfolio of road projects and other infrastructure and real estate developments.
Zensar Technologies is an IT company that ended the 2011 fiscal year strongly positioned for growth. The acquisition of Akibia in November 2010 makes Zensar a leader in infrastructure management among midcap IT companies. Zensar has also reorganized around focus verticals, which will allow it to better cross-sell services and mine existing clients. The company now has a robust business model and stronger financials than many peers, including better margins, capital efficiency, and free cash flow generation.
Four s weekly pe track 30th july - 5th august 2012Four-S
During the week of July 30th to August 5th, there were 12 private equity deals worth $1.1 billion compared to 7 deals worth $34.2 million the previous week. The largest deal was Bain Capital Partners agreeing to buy 30% of Genpact for $1 billion. Other deals included L Capital investing $19.6 million in PVR, Oman India Joint Fund investing $13 million in Solar Industries India, and Vistaar Financial Services raising $7.2 million from Lok Capital and others. Private equity activity in India continued with deals across sectors such as IT/ITeS, manufacturing, retail, and financial services.
Four s fortnightly logistics track 7th august - 20th august 2012Four-S
- Future Supply Chain Solutions plans to raise $1 billion in a second round of private equity funding to double its warehousing capacity. It had previously raised $30 million in 2009.
- Gateway Distriparks reported revenues of $110 million for 2012-13, down from $120 million the previous year, while net profits fell to $33 million from $40 million.
- Gateway Distriparks aims to increase container freight station capacity to 560,000 TEUs this year and resume full operations at facilities in Punjab and Kochi.
Four s fortnightly education track 6th august - 20th august 20123Four-S
The document summarizes the following:
1) The Central Board of Secondary Education (CBSE) and the Pearson Foundation will set up a centre for assessment, evaluation and research, marking the first concrete move by the Indian government towards fostering public-private partnership (PPP) in education.
2) The centre will focus on developing research and assessment capabilities and resources for CBSE, its network of schools and teachers, focusing on international best practices in school-based assessment, teaching techniques and high-stake examinations.
3) While CBSE will provide infrastructure, Pearson will take care of operational expenditure, including teacher salaries, in the initial two-year phase as the government seeks to improve education access and quality
Four s weekly pe track 30th july - 5th august 2012Four-S
Bain Capital bought a 30% stake in Genpact for $1bn, the largest PE deal of the week. L Capital invested $19.6mn in PVR and its subsidiary to focus on in-mall entertainment. Oman India Joint Investment Fund invested $13mn in Solar Industries India, an industrial explosives maker, for a 4.28% stake.
Four s fortnightly logistics track 7th august - 20th august 2012Four-S
The document discusses several logistics industry news items:
1) Dempo Group acquired a controlling stake in shipyard Modest Infrastructure for $140 million to expand into shipbuilding and repair.
2) Future Supply Chain Solutions plans to raise $1 billion to double its warehousing capacity.
3) Gateway Distriparks expects higher profits this year from new container freight stations becoming operational.
4) Private equity firm GTI Capital invested in foods logistics company Brattle Foods to expand its facilities.
Four s weekly pe track 9th july - 15th july 2012Four-S
The document summarizes recent private equity deals in India during the week of July 8th to July 15th, 2012. It discusses 5 PE/VC deals worth a total of $66.5 million, including Carlyle buying a 9.96% stake in Infotech Enterprises for $38 million. It also mentions Big Shoe Bazaar raising $18 million in Series C funding led by Fidelity Growth Partners and Qualcomm Ventures, and Mobikon Asia raising $1.7 million from Jungle Ventures and others. SAIF Partners is also described as buying an additional 2.78% stake in Blue Star for $8.8 million.
The document provides an overview of the logistics and supply chain sector in India. It notes that the sector size was around US$XXX billion in 2010-11, and is expected to grow to US$XXX billion by 2014-15 and US$XXX billion by 2019-20. Road transport is the largest segment currently, generating around US$56 billion in 2010-11. The executive summary highlights several attractive segments within the industry such as EXIM logistics, agri logistics, and third-party logistics. The report also profiles major listed and unlisted companies operating in the Indian logistics space.
Four s weekly pe track 28th may-3rd june2012Four-S
1) During the week ended June 3rd, 2012 there were 8 PE/VC deals worth $32.1 million compared to 9 deals worth $39 million the previous week.
2) The largest deal was Carlyle Ventures investing Rs 600 million ($10.7 million) for a 2% stake in South Indian Bank Limited.
3) Tiger Global and SAIF Partners invested $10 million in online retailer Zovi.com for growth stage funding.
Four s fortnightly mediatainment track 18th may - 31st may 2012Four-S
- India's GDP declined to a 9 year low, which will negatively impact media industry ad revenues in FY2013 as they are dependent on GDP. Zee forecasts 8-10% industry growth for FY2013 but aims to grow faster through market share gains and subscription revenue increases.
- Regional media and retail advertising performed better than national players. Print players expanded geographically but faced higher newsprint costs. Radio players expect over 10% revenue growth.
- The Indian M&E sector is reinventing itself with multiple revenue streams, geographic and digital expansion, supported by government regulatory moves around digitization and spectrum auctions.
Four s weekly pe track 28th may-3rd june2012Four-S
1) During the week ended June 3rd, 2012 there were 8 PE/VC deals worth $32.1 million compared to 9 deals worth $39 million the previous week.
2) The largest deal was Carlyle Ventures investing Rs 600 million ($10.7 million) for a 2% stake in South Indian Bank Limited.
3) Tiger Global and SAIF Partners invested $10 million in online retailer Zovi.com for growth stage funding.
India's largest solar program in Gujarat has cut rates paid to utilities for solar power by up to 33% as global panel prices have declined by more than half. The new rates for projects commissioned after January 28th will be Rs 9.98/kWh for the first 12 years and Rs 7/kWh for the next 13 years, down from Rs 15/kWh. India is lowering clean energy subsidies as equipment costs plunge. The document also provides an overview of cleantech private equity deals in the last 6 months of 2011 and first quarter of 2012, totaling $28.3 million, and information on carbon credit prices and clean energy news updates.
Four s weekly pe track 2nd april - 8th april 2012Four-S
During the week ended April 8th, 2012, there were 7 private equity deals worth $217 million compared to 12 deals worth $39.7 million the previous week. The largest deal was Advent International's $105 million investment in CARE Hospitals. Additionally, GIC and Baring PE invested $100 million in Marico Ltd and India Agri Business Fund invested $9.8 million in Super Agri Seeds. There were also smaller deals involving HMS Infotech, Savaari Car Rentals, and Godrej Landmark Redevelopers. Healthcare continues to be an active sector for private equity deals in India.
The document provides an overview of the solar energy sector in India. It notes that India has significant untapped solar potential but has realized less than 20% of its renewable energy capacity. Solar PV is the main technology used in India, concentrated in small-scale applications and lighting. Key challenges include the high cost of solar power generation due to high capital costs. The National Solar Mission aims to increase solar capacity through generation incentives and policies supporting manufacturers. Several companies are profiled that manufacture solar components and develop utility-scale solar plants in India.
Four s weekly pe track 19th march - 25th march 2012Four-S
During the week, there were 7 PE/VC deals worth $35 million compared to 10 deals worth $302.5 million the previous week. The largest deal saw Parsvnath Developers raise $23.6 million from Kotak Realty Fund for a township project in Gurgaon. There were also PE investments in DTL Ancillaries, Prajay Engineers, Akshara Foundation, and Edutor Technologies. In M&A, Amcor acquired Uniglobe Packaging for $20.7 million in the largest deal of the week.
Four s fortnightly education track 15th march - 31st march 2012Four-S
The Indian government has invited private companies to partner in opening 2,500 secondary schools over the next five years. Companies can qualify for schools based on their net worth, experience running schools, and deposit amounts. The government will provide infrastructure grants and pay for education costs of underprivileged students. Other news included the AICTE banning new engineering and management colleges, plans for a common medical entrance exam in 2013, and 76% of Right to Education violations remaining unresolved. Private investments in the education sector included deals by Omidyar Network, Mumbai Angels, and Hyderabad Angels. Stocks of major education companies like Core Education and Educomp showed mixed performance over the last year.
Four s fortnightly pharma health track 23th january - 5th febuary 2012Four-S
The document is a newsletter on the Indian healthcare industry from Four-S Services covering the period of January 23rd to February 5th, 2011. It discusses positive quarterly results for major healthcare companies in India with 28% year-over-year revenue growth. It also summarizes Dr. Reddy's Laboratories quarterly results with an 87.8% increase in net profit. The newsletter provides updates on private equity investment activity, mergers and acquisitions, regulatory news, and upcoming events in the healthcare sector.
Four s weekly pe track 16 january - 22nd january 2012Four-S
During the week of January 16-22, 2012 there were 10 private equity deals worth $281.2 million. The largest deal was Temasek Holdings acquiring a 4.9% stake in Godrej Consumer Products for $135 million. There were also investments in healthcare, real estate, technology, and other sectors. Private equity firms were actively fundraising, investing, and seeking exits during this period.
Explore the world of investments with an in-depth comparison of the stock market and real estate. Understand their fundamentals, risks, returns, and diversification strategies to make informed financial decisions that align with your goals.
13 Jun 24 ILC Retirement Income Summit - slides.pptxILC- UK
ILC's Retirement Income Summit was hosted by M&G and supported by Canada Life. The event brought together key policymakers, influencers and experts to help identify policy priorities for the next Government and ensure more of us have access to a decent income in retirement.
Contributors included:
Jo Blanden, Professor in Economics, University of Surrey
Clive Bolton, CEO, Life Insurance M&G Plc
Jim Boyd, CEO, Equity Release Council
Molly Broome, Economist, Resolution Foundation
Nida Broughton, Co-Director of Economic Policy, Behavioural Insights Team
Jonathan Cribb, Associate Director and Head of Retirement, Savings, and Ageing, Institute for Fiscal Studies
Joanna Elson CBE, Chief Executive Officer, Independent Age
Tom Evans, Managing Director of Retirement, Canada Life
Steve Groves, Chair, Key Retirement Group
Tish Hanifan, Founder and Joint Chair of the Society of Later life Advisers
Sue Lewis, ILC Trustee
Siobhan Lough, Senior Consultant, Hymans Robertson
Mick McAteer, Co-Director, The Financial Inclusion Centre
Stuart McDonald MBE, Head of Longevity and Democratic Insights, LCP
Anusha Mittal, Managing Director, Individual Life and Pensions, M&G Life
Shelley Morris, Senior Project Manager, Living Pension, Living Wage Foundation
Sarah O'Grady, Journalist
Will Sherlock, Head of External Relations, M&G Plc
Daniela Silcock, Head of Policy Research, Pensions Policy Institute
David Sinclair, Chief Executive, ILC
Jordi Skilbeck, Senior Policy Advisor, Pensions and Lifetime Savings Association
Rt Hon Sir Stephen Timms, former Chair, Work & Pensions Committee
Nigel Waterson, ILC Trustee
Jackie Wells, Strategy and Policy Consultant, ILC Strategic Advisory Board
How Poonawalla Fincorp and IndusInd Bank’s Co-Branded RuPay Credit Card Cater...beulahfernandes8
The eLITE RuPay Platinum Credit Card, a strategic collaboration between Poonawalla Fincorp and IndusInd Bank, represents a significant advancement in India's digital financial landscape. Spearheaded by Abhay Bhutada, MD of Poonawalla Fincorp, the card leverages deep customer insights to offer tailored features such as no joining fees, movie ticket offers, and rewards on UPI transactions. IndusInd Bank's solid banking infrastructure and digital integration expertise ensure seamless service delivery in today's fast-paced digital economy. With a focus on meeting the growing demand for digital financial services, the card aims to cater to tech-savvy consumers and differentiate itself through unique features and superior customer service, ultimately poised to make a substantial impact in India's digital financial services space.
Budgeting as a Control Tool in Government Accounting in Nigeria
Being a Paper Presented at the Nigerian Maritime Administration and Safety Agency (NIMASA) Budget Office Staff at Sojourner Hotel, GRA, Ikeja Lagos on Saturday 8th June, 2024.
Every business, big or small, deals with outgoing payments. Whether it’s to suppliers for inventory, to employees for salaries, or to vendors for services rendered, keeping track of these expenses is crucial. This is where payment vouchers come in – the unsung heroes of the accounting world.
Monthly Market Risk Update: June 2024 [SlideShare]Commonwealth
Markets rallied in May, with all three major U.S. equity indices up for the month, said Sam Millette, director of fixed income, in his latest Market Risk Update.
For more market updates, subscribe to The Independent Market Observer at https://blog.commonwealth.com/independent-market-observer.
Discover the Future of Dogecoin with Our Comprehensive Guidance36 Crypto
Learn in-depth about Dogecoin's trajectory and stay informed with 36crypto's essential and up-to-date information about the crypto space.
Our presentation delves into Dogecoin's potential future, exploring whether it's destined to skyrocket to the moon or face a downward spiral. In addition, it highlights invaluable insights. Don't miss out on this opportunity to enhance your crypto understanding!
https://36crypto.com/the-future-of-dogecoin-how-high-can-this-cryptocurrency-reach/
South Dakota State University degree offer diploma Transcriptynfqplhm
办理美国SDSU毕业证书制作南达科他州立大学假文凭定制Q微168899991做SDSU留信网教留服认证海牙认证改SDSU成绩单GPA做SDSU假学位证假文凭高仿毕业证GRE代考如何申请南达科他州立大学South Dakota State University degree offer diploma Transcript
Economic Risk Factor Update: June 2024 [SlideShare]Commonwealth
May’s reports showed signs of continued economic growth, said Sam Millette, director, fixed income, in his latest Economic Risk Factor Update.
For more market updates, subscribe to The Independent Market Observer at https://blog.commonwealth.com/independent-market-observer.
Economic Risk Factor Update: June 2024 [SlideShare]
Four s fortnightly pharma health track 23rd april - 5th may 2012
1. FOUR-S PharmaHealth Track
23thApr– 5thMay’12
PharmaHealth TRACK
Newsletter on Indian Healthcare Industry
Top Story Content
Cipla makes significant price cuts on 3 cancer drugs
Private Equity 2
Taking advantage of the economies of scale it has achieved, Cipla has
slashed the prices of three of its cancer drugs by significant amounts, a
move likely to further complicate efforts by big Western pharmaceutical Mergers & Acquisitions 3
companies seeking to develop their businesses in India. Cipla's decision
to slash prices comes only weeks after India's patent authority forced News Update 4
Germany's Bayer AG to grant a license to another Indian generic drug
producer for its kidney and liver cancer medicine Nexavar
Regulatory Developments 5
For the kidney cancer drug, Cipla has slashed its prices on generic
Sorafenib to `6,840 from ` 27,950. Sorafenib was recently in the news Upcoming Events 6
when the Patent Office issued a compulsory licence allowing Natco to
make a generic copy of the drug, on the payment of a royalty to the
Stock Market Update 7
innovator company, Bayer.
Natco had priced it at about ` 8,900, while Bayer’s price on its branded Peer Benchmarking 7
Sorafenib (Nexavar) stands at `2.8 lakh.
About Four-S Services 9
For lung cancer drug Gestinib, originally made by Astra Zeneca under the
name Iressa, Cipla has cut its prices to ` 4,250 from ` 10,200. Brain
tumour drug Temozolamide is available in three strengths and is
originally made by Schering. Cipla has reduced prices for all the three
strengths; On the 20mg pack of five, prices have come down to ` 480
from ` 1,875; on the 100mg strength prices have been reduced
to ` 2,400 from ` 8,900 and the 250mg is prices at ` 5,000 now
from ` 20,250 earlier.
About Four-S Services
Four-S Services is India's leading provider of Research, Financial Consulting and Investment Banking services with offices in Gurgaon, Mumbai and
Bangalore. We have a proven track record of consistently delivering high quality solutions, enabling our clients to improve the effectiveness of decision
making and acting as a catalyst in achieving business success. We have executed more than 120 mandates across diverse range of industries including
Education, Financial Services, Infrastructure, M&E, IT-ITeS, Auto and Auto ancillaries, Retail, Real Estate and Textile etc
Our Services:
Strategy Consulting Research Support
Business Planning Valuation Services
Investment Banking Investor Relations & IPO Consulting
For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
Research Desk
Four-S Services is India's leading provider of high-end research, financial consulting and Investment banking services. We have executed projects for
prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s Top 5 PE
Funds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
2. FOUR-S PharmaHealth Track
Investment Activity last 1 year..
Date Investor(s) Target Stake (%) Amount ($mn) Business Stage
5-May-2011 Sabre Partners SRL 4 112 Diagnostics Growth
Aquarious India,
17-Jun-2011 Vaatsalya NA 10 Hospitals Growth
SeedFund
Catamaran, Reliance VA,
20-Jun-2011 Wellspring Healthcare NA 4.6 Hospitals Growth
Bluecross BlueShield VP
23-Jun-2011 HDFC PE Angels Health Pvt Ltd 12 0.6 Online Healthcare Early
Super specialty
10-Aug-2011 Matrix Partners Kids Clinic NA 10 Early
hospital chain
28-Sep-2011 Sequoia Capital Moolchand Medcity NA 22.0 Hospitals Growth
Helion Ventures, Nexus
10-Oct-2011 Eye-Q NA NA Hospitals Growth
Ventures
28-Nov-2011 Fidelity Growth Partners XCyton Diagnostics NA NA Diagnostics Growth
12-Jan-2012 NEA, DaVita Inc NephroLife Care NA 25.0 Hospitals Growth
Sequoia Capital,
11-Jan-2012 Healthkart.Com NA 5.1 Health Services Early
Omidyar Network
18-Jan-2012 Olympus Capital DM Healthcare NA 100.0 Hospitals Growth
20-Jan-2012 Songs Investments Be Well Hospitals NA NA Hospitals Growth
OrbiMed, Ascent Kerala Institute of Medical
25-Jan-2012 NA 33.3 Hospitals Late
Capital Science
20-Feb-2012 Sahyadri Hospital IDFC Project Equity NA 38 Hospitals Late
Accentia Technologies Berggruen Holdings,
28-Feb-2012 NA NA Health Services PIPE
Ltd Cycladic Capital
15-Mar-2012 Vasan Healthcare GIC 100 NA Hospitals Late
2-Apr-2012 Advent International Care Hospitals NA 105 Hospitals Late
Accel Partners and IDG
27-Apr-2012 Forus Health NA 5 Health Services Early
Ventures India
Four-S Indian PE Directory 2010” – A Guide to choosing private equity partners
Detailed listing of ~330 Active PE/VC Investors in India - PE/VC players that have invested in the past 3 years.
A first-of-its-kind, the directory offers “Deal History” in India for individual investor.
Management, investment profile and Contact details.
Source: Four-S Database
User-friendly Spreadsheet Format.
It comes from Four-S Services, the most trusted deal information bank in India.
Research Desk
Four-S Services is India's leading provider of high-end research, financial consulting and Investment banking services. We have executed projects for
prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s Top 5 PE
Funds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
3. FOUR-S PharmaHealth Track
Mergers & Acquisition
Date Investor(s) Target Stake Amount ($mn) Business
(%)
15-Jun-2011 Lupin Goanna Brand NA NA OTC
17-Jun-2011 Zydus Nesher Pharma unit NA NA Generic
19-Jul-2011 Shilpa Medicare Nu Therapeutics 50 NA Pharma
21-Jul-2011 Dr Reddy’s Laboratories JBCL-Russia-CIS prescription products 100 30.5 Pharma
28-Jul-2011 Cadila Healthcare Bremer Pharma 100 NA Pharma
3-Aug-2011 Danone Wockhardt 's nutrition business 100 355 Pharma
9-Aug-2011 Ipca Labs Onyx Research 100 7.5 Healthcare Services
10-Aug-2011 Fortis Hoan My Medical 65 64 Hospitals
12-Sep-2011 Vivimed Labs Octtantis Nobel Labs Ltd 50 NA Pharma
8-Oct-2011 Akorn Inc KilitchDrugs (India) Ltd NA 40.1 Pharma
12-Oct-2011 Life Healthcare Group Max Healthcare Ltd. NA 103.1 Hospitals
Universal Medicare - branded
Pharma
4-Nov-2011 Aventis Pharma nutraceutical formulations biz NA 114.0
Shalaks Pharmaceuticals -
Pharma
14-Nov-2011 Invida Group dermatology and baby care 100 19.1
18-Nov-2011 Lupin Limited I'rom Pharma 100 NA Pharma
24-Nov-2011 SOHM Inc Novatrend Medicament NA NA Pharma
Transgene Biotek bio generic product
Pharma
23-Nov-2011 TSS EXPORT GmbH FZE - Erythropoietin 100 5.0
28-Nov-2011 Vivimed Labs Uquifa 100 55.0 Pharma
17-Jan-2012 Dishman Pharma Creapharm Parenterals 100 NA Pharma
24-Jan-2012 Watson Pharmaceuticals Ascent Pharma Health Ltd. NA 393 Pharma
1-Feb-2012 Fortis Healthcare RadLink-Asia Pte Ltd 85 50 Diagnostic
2-Feb-2012 Aanjaneya Lifecare Apex Drugs and Intermediaries Ltd 100 50 Pharma
Hospitals
1-Feb-2012 Fortis Healthcare RadLink-Asia Pte Ltd 85 50
Hospitals
6-Feb-2012 Nova Medical Centers Helios Hospitals 100 NA
Hospitals
6-Feb-2012 Radiant Life Care Guru Harkishan Hospital, Delhi NA 77
29-Feb-2012 Rapid Nutrition Cheminnova Remedies 74 NA Pharma
22-Mar-2012 B Braun Ahlcon Parenterals (India) Ltd 26 17 Pharma
26-Apr-2012 Strides Arcolab Ltd Star Drugs' Formulations Plant 100 23.8 Pharma
Source: Four-S Database
Research Desk
Four-S Services is India's leading provider of high-end research, financial consulting and Investment banking services. We have executed projects for
prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s Top 5 PE
Funds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
4. FOUR-S PharmaHealth Track
News Update
Healthcare & Pharmaceutical Sector been inspected by leading regulators like the US FDA, UK MHRA,
WHO, Australian TGA, and Japan’s MHLW.
1.) Pharmaceutical Sector
ChrysCap to buy ` 3bn stake in Intas Pharmaceuticals
Strides Acrolab buys injectable facility for ` 1.25bn
Private equity firm Chrys Capital is buying an additional stake
Strides Arcolab's wholly owned subsidiary Agila
in Intas Pharmaceuticals for ` 3bn after the Ahmedabad-based
Specialities acquired Sterile Formulations facility located at
drug maker deferred its IPO due to volatile market conditions.
Hosur from Star Drugs and Research Labs. The consideration for
The deal will increase ChrysCapital's holding in the company to
the facility is approximately ` 1.25bn and is being funded from
over 15% from the current 11.3%.
cash in hand and internal accruals
The company will go for the public issue when the market
The acquisition by Bangalore-based pharmaceutical firm Strides
stabilizes. The company will file its documents for the public
Arcolab was to expand core injectable business. This timely
issue again in the next few months and the IPO is expected to hit
acquisition brings into our fold, an asset which is of immediate
the market late next year. The drug maker has been valued at
importance given the demand for Sterile injectables worldwide.
over ` 50bnand the PE fund's stake will be in the "high teens."
The buy will give the Bangalore-based firm market advantage to
set up and commercialise a Greenfield project that can take The ` 27bn drug maker is among the country's top 10 players by
anywhere between 4-5 years. sales, with exports accounting for about 40% of its total global
Venus Remedies developing new cancer drug delivery sales. It is among the fastest-growing drug makers in the
technology country, having posted a CAGR of about 30% over the past five
years.
Venus Remedies is developing a new drug delivery platform that Ranbaxy launches first indigenous malaria drug
promises to reduce side effects and cost of cancer medicine by
as much as one-sixth. Ranbaxy Laboratories, India's largest drug maker, is launching
the country's first indigenously developed new medicine,
The company has designed a new drug delivery technology, drug
a malaria drug, that promises to boost the new drug
protein polymer conjugate that has been found to deliver cancer
drug at the targeted (affected) organ for breast and ovarian development abilities of the Indian pharma industry.
cancer during pre-clinical studies. The patented platform will
The antimalaria drug, a combination of two molecules --
enable a patient to reduce intake of drug by 4-6 times, thus
arterolane maleate and piperaquine phosphatethe -- is expected
reducing the toxicity level and cost of medicine.
to be priced at a significant discount, as low as one third, to
The company believes the technology can be used to treat all some alternatives. The raw material for the drug is synthetically
forms of solid tumours and will soon start clinical studies to made which will allow the company to address supply concerns.
check the same. The Chandigarh-based drug company plans to At present, malaria drugs are based on artemisinin, which is
launch the technology in the next 2-3 years. It plans to rope in a derived from plants. India has to depend on imports of the raw
partner for the clinical studies and is also open monetizing the material and there are volatilities in prices and supply.
technology.
Cipla, DNDi to launch new malaria drug
Lupin to set up New Formulations manufacturing facility In
MIHAN Cipla plans to launch fixed-dose combination anti-malarial drug
in India in partnership with non-profit organisation, Drugs for
Lupin Ltd has broken ground to set up a new state-of-the-art Neglected Diseases Initiative (DNDi).
formulation manufacturing facility at the Special Economic Zone
(SEZ), MIHAN, Nagpur. The Greenfield plant will take close to a The company has collaborated with DNDi to launch fixed-dose
year to being set up. combination of Artesunate (AS) and Mefloquine (MQ) to treat
malaria caused by microorganism 'P falciparum'.
Lupin today operates 11 world class manufacturing facilities
spread across India & Japan. Almost all of Lupin’s facilities have This new fixed-dose combination treatment will be introduced
in India under the brand name 'Mefliam Plus'. The product will
Research Desk
Four-S Services is India's leading provider of high-end research, financial consulting and Investment banking services. We have executed projects
for prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s
Top 5 PE Funds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
5. FOUR-S PharmaHealth Track
be launched in India and Malaysia soon where it has already 3.) Regulations/Legal
been registered.
Dr Reddy's gets US nod for osteoporosis drug
2.) Healthcare
Drugmaker Dr Reddy's Laboratories has received U.S. Food and
Abbott Laboratories in pact with Biocon to develop nutrition Drug Administration's approval for selling ibandronate sodium
products tablets used to treat osteoporosis. The tablets are the generic
version of Boniva, a brand sold by a unit of Swiss drugmaker
Abbott Laboratories will collaborate with Bangalore-based Roche.
Biocon to establish a research and development centre to
develop nutrition products in India. HC grants relief to Troikaa in patent case; restrains two firms
from selling Dynapar injections
Abbott Nutrition Centre, India will work with Syngene, the
contract research arm of Biocon, to develop affordable products Gujarat High Court has granted a temporary relief to Troikaa
for maternal, child nutrition and diabetes care. Pharmaceutical, restraining two pharma companies,
Ahmedabad-based Lincoln Pharmaceuticals and on Delhi-based
Accel Partners, IDG Ventures to invest $5 million in Forus Akums Drug & Pharmaceuticals Ltd, from making and selling the
Health patented versions of diclofenac injection. The Ahmedabad-
based company had patented diclofenac injection and sells it
Two marquee venture capital firms, Accel Partners and IDG under the brand name Dynapar AQ. As per industry estimates,
Ventures, are backing a two-year-old medical devices maker, Troikaa earns about 50% of its revenues from Dynapar.
underscoring the rising interest in healthcare ventures amongst
risk capital investors.
Orchid Pharma receives US FDA approval for Naratriptan
tablets
The two firms will together invest $5 million in Forus Health
which has developed a low-cost portable ophthalmology device, Orchid Chemicals & Pharmaceuticals Ltd has received approval
called '3nethra'. from US FDAfor its ANDA ( Abbreviated New Drug Application)
forNaratriptan tablets in the 1 mg and 2.5 mg strengths.
The device priced at one-sixth the cost of other comparable
Naratriptan tablets are the generic equivalent of GSK's Amerge
devices can identify multiple diseases such as cataract,
tablets
glaucoma, diabetic retina and refraction said K Chandrasekhar,
chief executive officer of Forus, who plans to use the funding to
Wockhardt launches generic Parkinson's treatment drug in US
hire talent and expand marketing across emerging markets such
as Africa, Latin America as well as the United States.
Drug maker Wockhardt has launched a generic version of Orion
Corporation's Parkinson's treatment drug Stalevo in the US, with
The medical device industry in India is set to grow from $2
180 days of marketing exclusivity.
billion in 2011 to $6 billion by 2015, according to industry
tracker, UBM Canon.
The company said its generic copy is of four strengths (50mg,
75mg, 125mg and 200mg) of the triple-drug combination
NephroPlus to set up 40 kidney care clinics in North India over
product containing levodopa, carbidopa and entacapone.
next 3 years
Wockhardt was the first-to-file with paragraph-IV certification
Hyderbad-based NephroPlus, a kidney care clinics chain, will set
on four out of six strengths of this product. Pursuant to a
up 40 of its proposed 100 dialysis centres in North India over the
settlement of the litigation between Wockhardt and Orion
next three years. From the present seven kidney care clinics,
Corporation, Finland, the two parties came to an arrangement
company is expanding their operations, and will set up 100
to launch an authorised generic version with 180-days of
kidney care and dialysis clinics across the country. Of these, 40
exclusivity. The total market for this product in the US is about
will come up in North India. The company, which received first
USD 55 million for the above four strengths and even after the
round of funding from venture capital firm Bessemer Venture
180-days exclusivity the number of competitors to enter the
Partners last year, was now looking forward for right
market is expected to be very limited.
partnerships towards its plan of setting up the 100 centers.
Research Desk
Four-S Services is India's leading provider of high-end research, financial consulting and Investment banking services. We have executed projects
for prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s
Top 5 PE Funds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
6. FOUR-S PharmaHealth Track
Global News Update
The sellers are comprised of a consortium of private equity
funds led by Nordic Capital, DLJ Merchant Banking (a Credit
AstraZeneca to acquire Ardea Biosciences for US$1bn Suisse affiliate) and Avista Capital Partners.
AstraZeneca and Ardea Biosciences, Inc. (Ardea) have entered The acquisition creates another strong global growth platform
into a definitive merger agreement, pursuant to which for Sandoz, the generic pharmaceuticals division of Novartis.
AstraZeneca will acquire Ardea, a San Diego, California-based Based on 2011 IMS data, the combined businesses will become
biotechnology company focused on the development of small- the #1 global company in generic dermatology medicines, with
molecule therapeutics. Ardea’s clinically most advanced product estimated annual global sales of nearly USD 620 million,
candidate, lesinurad (formerly known as RDEA594), is currently primarily in the US.[1] Fougera has strong dermatology
in Phase III development as a potential treatment for the chronic development and manufacturing expertise, with numerous
management of hyperuricaemia in patients with gout. launches planned for 2012 and beyond.
Under the terms of the agreement, AstraZeneca will acquire GSK confirms offer to acquire Human Genome Sciences for
Ardea for US$32 per share which represents a total cash value US$13.00 per share in cash
of approximately US$1.26 billion, including existing cash. This
represents a premium on the value of Ardea’s stock of 50% GlaxoSmithKline plc made an offer to the Board of Directors of
based on the one month volume-weighted average price Human Genome Sciences (HGS, NASDAQ: HGSI) on 11th April
(VWAP) and 54% based on the closing price on Friday, 20 April proposing to acquire all of the outstanding shares of HGS for
2012. US$13.00 per share in cash.
Sandoz to acquire Fougera Pharmaceuticals, becoming the
number one generic dermatology medicines company
Novartis has signed a definitive agreement to acquire specialty
dermatology generics company Fougera Pharmaceuticals. Under
the terms of the agreement, Novartis will acquire the business,
which is based in Melville, New York, for USD 1.525 billion in an
all-cash transaction.
Events Calendar
7th India International Medical Equipment Expo US-India BioPharma & Healthcare Summit 2012
Date: Jul 20-22, 2012 Date: 11 May 2012
Venue: Chennai, Venue: Hyatt Regency Cambridge, Massachusetts, US
Organizer: Paramount Exihibitors Organizer: USAIC
Tel: +91-172-2274801-02,4699301-02 Tel: 781 586-1212
E-mail: info@usaindiachamber.org
Medicall Banglore India Bio
Date: 3 Aug -6 Aug, 2012 Date: Jun 2-4, 2012
Venue: Chennai Trade & Convention Centre, Chennai Venue: Hotel Lalit Ashok, Banglore
Webmail: info@medicall.in
Tel: +91 80 4113 1912 / 13
Organizer : Medexpert Business Consultants
Email: enquiry@bangalorebio.in
www.medicall.in
/
Research Desk
Four-S Services is India's leading provider of high-end research, financial consulting and Investment banking services. We have executed projects
for prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s
Top 5 PE Funds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
8. FOUR-S PharmaHealth Track
TTM Results
`in million
Revenue EBITDA PAT (After EI) Margins TTM
TTM TTM TTM TTM TTM TTM EBITDA
Companies Dec 10 Dec 11 YoY Dec 10 Dec 11 YoY Dec 10 Dec 11 YoY % NPM %
DR.REDDY'S L 70293 90326 22% 14311 21710 34% 8746 14141 38% 24% 16%
RANBAXY LABO 89582 99578 11% 18652 10848 -42% 17368 -28834 -266% 11% -29%
SUN PHARMACE 53383 71387 25% 19421 27389 29% 18398 25724 28% 38% 36%
CIPLA LTD. 58744 66936 12% 12806 15007 15% 10287 10462 2% 22% 16%
LUPIN LTD 55133 66307 17% 11727 13827 15% 8757 9551 8% 21% 14%
CADILA HEALTH 41626 49859 17% 9866 10449 6% 6508 6607 1% 21% 13%
AUROBINDO PH 42154 46877 10% 8778 3959 -122% 5600 -1068 624% 8% -2%
JUBILANT ORG 35349 39699 11% 6449 7650 16% 3009 1651 -82% 19% 4%
GLENMARK PHA 28631 37469 24% 6892 6270 -10% 4459 3932 -13% 17% 10%
APOLLO HOSPITAL 21935 26769 18% 3451 4356 21% 1638 2188 25% 16% 8%
GLAXOSMITH 21952 24331 10% 7157 8025 11% 5606 4286 -31% 33% 18%
IPCA LAB LTD 17681 22838 23% 3465 4387 21% 2341 2621 11% 19% 11%
OPTO CIRCUIT 13755 22387 39% 4366 5879 26% 3230 4751 32% 26% 21%
BIOCON LTD 19879 21689 8% 5381 5345 -1% 3306 3427 4% 25% 16%
PIRAMA HEALTH 28767 20055 -43% 2871 -211 1463% 128357 3549 -3517% -1% 18%
ORCHID CHEM 13847 17455 21% -1242 4517 127% 4894 901 -443% 26% 5%
Divi's Lab 11426 16069 29% 4607 6177 25% 3835 5059 24% 38% 31%
Standalone results for Cipla, Apollo, Orchid, Glaxosmith, Divis Lab and Ipca Lab
BSE Healthcare Index movement in last 2 weeks
Research Desk
Four-S Services is India's leading provider of high-end research, financial consulting and Investment banking services. We have executed projects
for prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s
Top 5 PE Funds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
9. FOUR-S PharmaHealth Track
Four-S Services Pvt Ltd
Founded in 2002, Four-S has a strong & successful track record of genuine, accurate and
objective advice to top Indian & global companies & PE Firms. Four-S has already proven
success in corporate finance, strategy consulting, fund-raising, investment banking and
investor relations mandates with 100+ corporates and large PE funds
Four-S, trusted advisor to top Indian & Global Cos
Offering comprehensive bouquet of services to Private Equity Funds
Research Desk
Four-S Services is India's leading provider of high-end research, financial consulting and Investment banking services. We have executed projects
for prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s
Top 5 PE Funds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com
10. FOUR-S PharmaHealth Track
About Four-S Services
Four-S Services provides customized business and financial research to organizations across the
globe. The company also provides Investor Relations consulting to corporate based on in-depth
sectoral and company research. The company has an impressive client profile and a team of senior
analysts covering key sectors including Finance & Banking, IT & Telecom, Retail, Media &
Entertainment, Pharmaceuticals, Infrastructure and Manufacturing amongst others. For further
information on the company please visit www.four-s.com
Disclaimer
The information contained herein has been obtained from sources believed to be reliable but is not necessarily complete and its
accuracy cannot be guaranteed. No representation, warranty, guarantee or undertaking, express or implied, is made as to the fairness,
accuracy or completeness of any information, projections or opinion contained in this document or upon which any such projections or
opinions have been based. Four-S Services Pvt Ltd. will not accept any liability, whatsoever with respect to the use of this document or
its content. This document has been distributed for information purposes only and does not constitute or form part of any offer or
solicitation of any offer to buy or sell any securities. This document shall not form the basis of and should not be relied upon in
connection with any contract or commitment whatsoever. This document is not to be reported or copied or made available to others.
The Company may from time to time solicit from, or perform consulting, or other services for, any company mentioned in this
document.
Research Desk
Four-S Services is India's leading provider of high-end research, financial consulting and Investment banking services. We have executed projects
for prestigious Indian as well as global corporations, investment banks, private equity funds, venture capitalists and hedge funds including India’s
Top 5 PE Funds. For further information, please contact Seema Shukla at seema@four-s.com or reach us as http://www.four-s.com